jetcityimage The U.K. health authorities on Tuesday recommended Eli Lilly’s ( NYSE: LLY ) obesity therapy, tirzepatide, allowing its use in the country’s healthcare system under more favorable terms than Novo Nordisk’s ( NVO ) rival drug, semaglutide.
The National Institute for Health and Care Excellence (NICE), which sets drug policy for the U.K.’s National Health Service (NHS), said that Lilly’s ( LLY ) GLP-1 agonist should be prescribed for people with at least one weight-related condition and a body mass index (BMI) of at least 35.
0. However, unlike Novo’s ( NVO ) semaglutide, NICE didn’t limit the treatment duration. Last year, the drug cost regulator issued final guidance for semaglutide under similar conditions, noting that the injectable should be used for obesity for a maximum of two years.
NICE will be open for public comments on tirzepatide use until June 25, and its final guidance will be issued before the end of October. More on Eli Lilly, Novo Nordisk, etc. Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Novo Nordisk: The Market Is Right, Don't Fight Against It Eli Lilly sees improving availability of GLP-1 drugs Mounjaro and Zepbound Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases.
